A retrospective observational study of molecular profiling in secondary cancer patients

A retrospective observational study of molecular profiling in secondary cancer patients - A retrospective observational study of molecular profiling in secondary cancer patients

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000053642

Enrollment

Registered

2024-02-19

Start date

2023-08-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

secondary cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients must be at least 20 years of age at the time of consent. Patients who have received systemic chemotherapy (including cytotoxic chemotherapy, molecular targeted therapy, and immune checkpoint inhibitors) in the past Patients diagnosed with a second cancer Patients who can provide tumor tissue. Cases in which Informed Consent for this study has been obtained (except for cases in which the patient has already died or is unable to give Informed Consent due to medical conditions, etc.).

Exclusion criteria

Exclusion criteria: No specific exclusion criteria are set.

Design outcomes

Primary

Measure	Time frame
Combined genotype and immune phenotype, biomarkers can classify the tumor immune microenvironment of secondary carcinoma cases, identify patients who will benefit from immune checkpoint inhibitors, and evaluate differences in therapeutic efficacy.	—

Countries

Japan

Contacts

Public ContactTakayuki Takahama

Kindai University Faculty of Medicine Department of Medical Oncology

takahama_t@med.kindai.ac.jp0723660221

Outcome results